Among 14,118 matched pairs of adults with atrial fibrillation and type 2 diabetes, starting tirzepatide was linked to lower risks of stroke and death than starting another GLP-1 drug, with absolute differences of 2.1 and 6.2 percentage points at one…
In the LEAP-Block trial, published Oct. 28, 2026, in JAMA, people with heart block who got left bundle-branch area pacing had death, heart failure events or pacemaker upgrade in 2.4% of cases at 24 months, vs. 12.5% with standard right…
In older US adults with atrial fibrillation and stage 4 or 5 kidney disease not on dialysis, apixaban halved ischemic stroke but raised major bleeding vs. no anticoagulant, while warfarin raised bleeding without clearly reducing stroke.